MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$883K, compared with $85K a year earlier.
Context
- Accumulated OCI amounted to 0.2% of total assets at the end of Q1 FY2026, up 0.1 pp from a year earlier.
- Accumulated OCI increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -1138.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- (228K) USD
- Year-over-year change
- -239.9%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (228K) | -239.9% |
| FY2024 | 2024-12-31 | 163K | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Accumulated OCI vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 Accumulated OCI of -$883K is the 10th highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of -1138.8% is the 8th highest of 9, against a peer median of -95.0%.
- Accumulated OCI amounts to 0.2% of total assets for MPLT, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.92M | +173.2% | — | 1.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $208K | +1464788732394466.3% | — | 0.1% |
| Mar 2026 | $13K | -7.1% | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | +100.0% | — | 0.0% |
| Mar 2026 | -$422K | -779.2% | — | 0.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$505K | -431.6% | — | 0.1% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | -$829K | -182.8% | +20.1% | 0.1% |
| Mar 2026 | -$883K | -1138.8% | — | 0.2% | |
| Mar 2026 | -$1.8M | -2091.5% | — | 0.6% | |
| Peer median (excluding MPLT) | $0 | -95.0% | +20.1% | 0.1% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.